23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
In the wake of a big data breach and a sizable new round of layoffs, 23andMe's handling of sensitive personal data is in the ...
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...
23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...
Me Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported its latest quarterly loss, shedding ...
The genealogy company’s CEO announced over 200 employees will be let go and it will also shutter its drug-development arm. I ...
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The ...
Millions of people have sent their DNA to be analyzed by 23andMe in order to learn their genealogy and risk for certain ...
To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. 23andMe said Monday it will lay ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback